These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Patient satisfaction and efficacy of switching from weekly bisphosphonates to monthly minodronate for treatment and prevention of glucocorticoid-induced osteoporosis in Japanese patients with systemic rheumatic diseases: a randomized, clinical trial. Tamechika SY; Sasaki K; Hayami Y; Ohmura SI; Maeda S; Iwagaitsu S; Naniwa T Arch Osteoporos; 2018 Jun; 13(1):67. PubMed ID: 29904824 [TBL] [Abstract][Full Text] [Related]
3. Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. De Nijs RN Minerva Med; 2008 Feb; 99(1):23-43. PubMed ID: 18299694 [TBL] [Abstract][Full Text] [Related]
4. [Secondary osteoporosis or secondary contributors to bone loss in fracture. Therapeutic strategy for glucocorticoid-induced osteoporosis]. Hayakawa N; Suzuki A Clin Calcium; 2013 Sep; 23(9):1337-44. PubMed ID: 23999371 [TBL] [Abstract][Full Text] [Related]
5. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. Saag KG; Shane E; Boonen S; Marín F; Donley DW; Taylor KA; Dalsky GP; Marcus R N Engl J Med; 2007 Nov; 357(20):2028-39. PubMed ID: 18003959 [TBL] [Abstract][Full Text] [Related]
10. Secondary osteoporosis: underlying disease and the risk for glucocorticoid-induced osteoporosis. Boling EP Clin Ther; 2004 Jan; 26(1):1-14. PubMed ID: 14996513 [TBL] [Abstract][Full Text] [Related]
11. [Glucocorticoid and Bone. Efficacy and safety of bisphosphonate in treatment of glucocorticoid induced osteoporosis]. Tanaka I Clin Calcium; 2014 Sep; 24(9):1371-8. PubMed ID: 25177010 [TBL] [Abstract][Full Text] [Related]